Overview

Quercetin Phytosome (marketed as Quercefit by Indena) is a patented formulation in which quercetin molecules are complexed with sunflower-derived phosphatidylcholine through hydrogen bonding and hydrophobic interactions in a 1:1 stoichiometric ratio, creating a phytosome delivery system. This complexation addresses quercetin's most significant pharmacological limitation — its extremely poor oral bioavailability, estimated at only 2% for standard quercetin due to low aqueous solubility, rapid intestinal glucuronidation by UDP-glucuronosyltransferases, sulfation by sulfotransferases, and extensive first-pass metabolism. Pharmacokinetic studies have demonstrated that quercetin phytosome achieves approximately 20-fold greater plasma quercetin levels compared to equivalent doses of unformulated quercetin, with enhanced and more sustained absorption kinetics.

The phytosome technology differs from liposomes in that the active compound is an integral part of the membrane structure rather than being encapsulated within an aqueous core. The phospholipid shell surrounds individual quercetin molecules, creating an amphiphilic complex that is miscible with both the aqueous intestinal environment and the lipid bilayer of enterocyte membranes. This facilitates transcellular absorption through the intestinal epithelium and provides some protection against rapid phase II conjugation in enterocytes. The result is not merely higher peak plasma levels but also a shift in the metabolite profile — with phytosome delivery, a greater proportion of quercetin reaches systemic circulation in its unconjugated (active) aglycone form compared to standard quercetin, where conjugated metabolites predominate.

Clinical studies with quercetin phytosome have demonstrated benefits at substantially lower doses than those typically required for standard quercetin. In trials examining upper respiratory health, quercetin phytosome at 500 mg/day reduced the incidence and severity of respiratory infections in athletes and community-dwelling adults. Studies in osteoarthritis have shown improvements in joint pain, stiffness, and function. The enhanced bioavailability also makes quercetin phytosome potentially more effective as a senolytic agent when combined with dasatinib, and more efficient at delivering quercetin's mast cell-stabilizing and anti-inflammatory benefits. Typical dosing ranges from 250-1000 mg/day of the phytosome complex (containing approximately 37% quercetin by weight). It represents the same phytosome platform used for other enhanced botanical extracts including curcumin phytosome (Meriva) and silybin phytosome (Siliphos).

Mechanism of Action

Mechanism of Action: Quercetin Phytosome

Quercetin phytosome (Quercetin Phytosome®/Quercesome™) is a patented formulation in which quercetin is complexed with sunflower-derived phosphatidylcholine in a defined molecular ratio, creating a phytosome (phyto-phospholipid) complex with dramatically improved pharmacokinetic properties.

Phytosome Technology and Bioavailability

Native quercetin has poor oral bioavailability (~2-5%) due to low aqueous solubility, extensive first-pass glucuronidation, and P-glycoprotein-mediated efflux. In the phytosome complex, quercetin forms hydrogen bonds with the phosphatidylcholine polar head group while the lipophilic phospholipid tails create a shell that: (1) increases apparent solubility in intestinal fluid; (2) protects against gastric and enzymatic degradation; (3) facilitates incorporation into mixed micelles; (4) enhances transcellular absorption through enterocyte membranes. Pharmacokinetic studies demonstrate 20-fold greater AUC and significantly higher Cmax compared to unformulated quercetin.

Anti-inflammatory Mechanisms

With therapeutically relevant plasma concentrations, quercetin phytosome effectively inhibits the NF-κB cascade: blocking IKKβ activity, preventing IκBα degradation, and suppressing p65 nuclear translocation. Clinical studies show significant reductions in high-sensitivity CRP, IL-6, and TNF-α. NLRP3 inflammasome inhibition reduces IL-1β and IL-18 release. COX-2 and 5-LOX inhibition further attenuates prostaglandin and leukotriene-mediated inflammation.

Mast Cell Modulation

The enhanced bioavailability allows quercetin to reach tissue concentrations effective for mast cell stabilization in vivo. This includes inhibition of Syk/PLCγ signaling, calcium influx blockade, and PKC inhibition, preventing histamine, tryptase, and leukotriene release from mast cells. Clinical implications include management of allergic rhinitis, urticaria, and mast cell activation disorders.

Senolytic and Anti-aging Properties

Quercetin phytosome delivers adequate quercetin concentrations to tissues harboring senescent cells, enabling effective PI3K/Akt inhibition and Bcl-2/Bcl-xL downregulation required for selective senescent cell apoptosis. This reduces the senescence-associated secretory phenotype (SASP) burden, with implications for aging-related chronic inflammation and tissue dysfunction.

Metabolic Benefits

Enhanced AMPK activation at achievable tissue concentrations improves insulin signaling, promotes GLUT4 translocation, enhances mitochondrial biogenesis through PGC-1α deacetylation by SIRT1, and supports healthy lipid metabolism. Clinical studies demonstrate improvements in fasting glucose, lipid profiles, and markers of metabolic syndrome.

Phosphatidylcholine Synergy

The phosphatidylcholine carrier itself provides additional benefits: supporting hepatocyte membrane integrity, contributing to acetylcholine synthesis, and facilitating quercetin incorporation into lipoproteins for sustained systemic distribution and tissue targeting.

Research

Safety Profile

Safety Profile: Quercetin Phytosome

Common Side Effects

• Generally well tolerated; phytosome formulation improves bioavailability by 20-fold, so lower doses are effective (250–500 mg/day)
• Mild gastrointestinal discomfort including nausea and bloating (less common than standard quercetin due to lower required doses)
• Headache and mild dizziness
• Mild tingling sensations reported in some users

Serious Adverse Effects

• Enhanced bioavailability means increased potential for drug interactions compared to standard quercetin at equivalent doses
• Nephrotoxicity risk from oxalate metabolites, though lower absolute doses may partially offset this concern
• Allergic reactions in individuals sensitive to soy lecithin (phospholipid component of phytosome) or quercetin
• Potential thyroid disruption with chronic high-dose use (quercetin inhibits thyroid peroxidase in vitro)
• Theoretical bleeding risk due to antiplatelet properties at higher effective concentrations

Contraindications

• Known allergy to quercetin, soy, sunflower lecithin (depending on formulation), or related flavonoids
• History of calcium oxalate kidney stones without medical oversight
• Severe renal impairment
• Concurrent cyclosporine therapy (enhanced bioavailability increases interaction risk)
• Pregnancy and lactation (insufficient safety data)

Drug Interactions

• Cyclosporine: Significantly increased risk of elevated cyclosporine levels due to enhanced quercetin bioavailability; avoid combination
• Anticoagulants/Antiplatelets: Enhanced bioavailability may amplify antiplatelet effects; monitor closely
• CYP3A4 and CYP2C9 substrates: Greater inhibitory potential due to higher plasma quercetin levels; monitor drugs with narrow therapeutic indices
• Fluoroquinolone antibiotics: May reduce efficacy; separate dosing by at least 2 hours
• Antihypertensives and antidiabetic agents: Additive effects on blood pressure and blood glucose more likely with enhanced absorption

Population-Specific Considerations

• Elderly: Use lower starting doses given enhanced bioavailability; monitor renal function and drug interactions
• Pediatric: No established safety data; not recommended for children
• Soy-allergic individuals: Check formulation; some phytosomes use sunflower lecithin as an alternative
• Kidney disease patients: Exercise greater caution than with standard quercetin due to higher systemic exposure
• Immunocompromised patients: Consult physician before use; quercetin has immunomodulatory properties

Pharmacokinetic Profile